Seeking Alpha
We cover over 5K calls/quarter
Profile| Send Message|
( followers)

iCAD, Inc. (NASDAQ:ICAD)

Q1 2014 Earnings Conference Call

May 6, 2014 17:00 ET

Executives

Anne Marie Fields - Vice President, LHA

Ken Ferry - Chief Executive Officer

Kevin Burns - Executive Vice President, Finance and Chief Financial Officer

Analysts

Brian Marckx - Zacks Investment Research

Bill Bonello - Craig-Hallum

Jeb Terry - Aberdeen Investment Management

Operator

Good day, ladies and gentlemen, and welcome to the Q1 2014 iCAD Incorporated Earnings Conference Call. My name is Chris and I’ll be your operator for today. (Operator Instructions) As a reminder, this conference is being recorded for replay purposes.

I would now like to turn the conference over to your host for today, Ms. Anne Marie Fields with LHA. Please proceed.

Anne Marie Fields - Vice President, LHA

Thank you. Good afternoon. This is Anne Marie Fields with LHA. Thank you all for participating in today’s call. Joining me from iCAD are Ken Ferry, Chief Executive Officer, and Kevin Burns, Executive Vice President, Finance and Chief Financial Officer.

Earlier this afternoon, iCAD announced financial results for the first quarter ended March, 31 2014. If you’ve not received this news release or if you’d like to be added to the company’s distribution list, please call LHA in New York at 212-838-3777 and speak with Carolyn Curran.

Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of iCAD. I encourage you to review the company’s filings with the Securities and Exchange Commission, including, without limitation, the company’s Forms 10-K and 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, May 6, 2014. iCAD undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call.

So with that said, I would like to turn the call over to Ken Ferry. Ken?

Ken Ferry - Chief Executive Officer

Thanks, Anne Marie. Good afternoon everyone, and thanks for joining us. We’re pleased today report another quarter’s strong financial results. This is our seventh consecutive quarter of delivering year-over-year growth in revenues and positive EBITDA. This solid performance could be attributed to the continued strong demand for our Therapy products as well as from continued growth in recurring revenue from our Cancer Detection products.

In addition, we significantly strengthened our balance sheet in the quarter with an underwritten public offering of common stock today at approximately $28 million to our balance sheet. Over time, we expect to use some of the proceeds to further accelerate market adoption in both the Therapy and Cancer Detection product areas. We also recently announced the termination of the revenue-sharing component for our debt facility with Deerfield. This actually removes the most costly component of our debt facility and significantly reduces our cash interest expense going forward. So, all in all, another strong quarter comparatively, where we continue to achieve considerable growth in recurring revenue, well significantly strengthening our balance sheet with the addition of the $28 million from the public offering of common stock.

So, now let me turn things over to Kevin Burns, for a detailed review of our financials and after which, I’ll make some additional comments on the business before we opening up the call to your questions. Kevin?

Kevin Burns - Executive Vice President, Finance and Chief Financial Officer

Thank you, Ken, and good afternoon, everyone. As Ken mentioned, 2014 has gotten off to a strong start with another quarter of solid revenue growth and positive adjusted EBITDA. Our investments in growth and market adoption are paying off. We’ve strengthened our balance sheet with a strategic offering that gives us a stronger foundation from which to expand the business. In addition, it provided us the flexibility to buyout the most expensive portion of our debt facility at favorable terms which will significantly lower our cash interest expense moving forward. So, with momentum in key corporate growth areas, we look forward to continuing to grow revenue, focus investment and market adoption while driving towards positive free cash flow. I believe iCAD is in the strong financial position as it has been in quite some time.

Now, let me move on to our quarterly financial performance. Let me remind you how we report revenue which is by the two main oncology areas in which we operate specifically Cancer Detection and Therapy. Our Cancer Detection revenue includes all of our image analyses and workflow products including mammography, MRI and CT CAD platforms as well as service and supplies revenue. Our Therapy revenue includes the Xoft Axxent Brachytherapy System, related accessories, supplies, services, and source agreements. Effective this quarter, we had request tight sales of balloon applicators and supply so that they are now included in Therapy service and supply revenue and we’ve also moved associated expenses to cost of service and supply revenue.

Turning now to a review of our revenue, total revenue for the first quarter increased 7.4% to $8.5 million, up from $7.9 million in the first quarter of 2013. This was driven by a 32% increase in our Therapy revenue, offset by 10% decline in Cancer Detection revenue. In the first quarter, our Therapy business increased $4.3 million in revenue with product revenue relatively to $2.1 million and service and supply revenue increasing 95% to $2.3 million. The growth in our recurring service and supply revenue reflects increased sales of balloon applicators combined with the growing install base and associated service and source revenue.

If you add the future recurring revenue associated with systems that are not yet clinically used, our total annualized recurring revenue run rate is approximately $10 million per year. On side note, we have a very healthy margin in our Therapy and service business in a low 70% range that has been and is expected to continue to improve over time. Total revenue for our Cancer Detection business in the first quarter was $4.2 million, a decline of 10% compared with last year’s first quarter. Product sales in the first quarter were $2.1 million down 23% from last year. The decrease was driven primarily by continued weakness in the 2D and analog markets, both domestically and outside of the U.S. This was partially offset by continued momentum in our MRI CAD product sales. Our subscription-based product and service revenue grew 7% to $2.1 million which continue to reflect our shift to leveraging the install base with new products and service agreement. Moving forward, we expect this recurring revenue to grow and remain an important contributor for our Detection business.

In summary, with solid growth in the Therapy side of the business, and we continue to increase the service component of our Cancer Detection business. Looking forward, on an annualized basis, our recurring revenue’s run rate is approximately $18.5 million from both side of the business and we will continue to focus on driving additional recurring revenue.

Looking now to the rest of P&L, gross profit for the first quarter of 2013 increased $5.9 million or 69.6% of revenue from $5.6 million or 71.2% of revenue for the first quarter of 2013. Our total products gross margin for the first quarter was 71.5%, which is down from an aggregate 73.7% for fiscal year 2013. The decline in product margin percent was driven by the higher mix of Therapy product revenues compared to Cancer Detection product revenue.

From a services margin standpoint, we continue to see services margin expansion from an average of 71.3% in 2013 to 73.4% in the first quarter. Overall, we may experience pressure in the short-term on our product margins as Therapy revenues become a larger component of our overall revenue. However, ongoing services margin expansion will result in total overall margin improvements with quarterly fluctuations. Throughout 2014, we believe gross margins will be in a low 70% range and growing to the mid 70% range in the back-half of 2015.

Total operating expenses for the first quarter of 2014 increased to $6.4 million from $6 million for the same period in 2013. We continue to make investments for growth, that include regional IORT and skin seminars, clinical trials, sales team expansion, medical trade shows and instrumental product development. As we discussed during our last call, we continue to see a majority of our skin business concentrated in the western region of the United States. This represents a very large market opportunity and is anchored by California which has one of the highest rates to skin cancer. However, we want to continue to expand our skin market opportunity and as a result, we are aggressively pursuing investments outside of this region.

Our initiatives are focused on developing key regional opinion leaders, generating claims data and working with our partners to support their expansion programs all in an effort for broader reimbursement and market coverage. In addition, we have developed programs focused on the breast market that are procedure or subscription-based as oppose to significant upturn capital. These investments will continue to be reflected in an increasing operating expense level throughout the year.

Turning now to our profit metrics, adjusted EBITDA was $447,000 for the first quarter of 2014 compared with $592,000 in the first quarter of last year. From a percentage standpoint, this was 5.2% of revenue in the first quarter and in line with 5.6% of revenue for fiscal year 2013. Again, we will continue to invest appropriately to drive additional growth, while balancing this with a goal toward longer term EBITDA expansion.

Looking at other income and expense items during the first quarter, we reported a $1.1 million gain due to the change in the fair value of warrants that we issued as part of our financing arrangement. Interest expense in the first quarter was $817,000, of which $582,000 is cash payable related to financing and capital lease obligations. The balance of $235,000 represented non-cash amortization of financing cost and settlement obligations. On a per share basis, our non-GAAP adjusted net loss for the first quarter of 2014 was $0.12 per share compared to a $0.11 per share last year.

Moving on to the balance sheet, we ended the year with $38.4 million in cash and equivalents with compared to $11.9 million as of December 31, 2013. On March 17th, we completed an underwritten public offer at 2.76 million shares at common stock at $11 per share. Proceeds from the offering were approximately 28.2 million after deducting underwriting discounts and operating expenses.

During the first quarter, we used $1.7 million in cash excluding the proceeds from the offering. As you know, from the quarterly standpoint, the first quarters typically are low point for cash on an annual basis. For the period ending March 31, we had larger than normal commissions performance payouts due to the strong financial performance in 2013. In addition, we had a small decrease in deferred revenue as we have moved towards agreement in payment terms for some of our larger customers to quarterly from annual. As a result of these factors, we used more cash than anticipated in the first quarter. In addition, we got sequential decrease in our DSOs to approximately 82 days from 84 days in the fourth quarter.

Before I hand the call back to Ken, I would like to summarize the termination of our revenue-sharing component of our debt facility. As you know, we have an outstanding $15 million debt facility at Deerfield. There were two components to this facility. The first is a $15 million note payable with a 5.75% interest rate on the outstanding principle. This has an annual cash cost to iCAD of $862,000. The second was a revenue-sharing agreement under which we paid on average 3.5% in revenues to Deerfield. In 2013, we paid Deerfield approximately $1.3 million under the revenue-sharing agreement which was an effective grade of approximately 9% on the outstanding $15 million. After a review of the facility, we decided it was an appropriate time to terminate the revenue-sharing component.

As a result, we paid $4.1 million to Deerfield and had no further revenue-sharing loyalty payment. In addition, Deerfield exercised their warrant which provided at approximately $1.6 million of cash. The net impact from these two transactions was a cash use of $2.5 million. With a March ending cash balance of $38.4 million plus the net cash impact of $2.5 million from the DSO transactions. This leads us to a $35.9 million of cash and $15 million of debt paid 5.75% interest rate. We believe the offering in our subsequent buy up as a revenue-sharing portion of our debt facility significantly strengthened our balance sheet and put us in a much stronger position to make select, strategic investment in key areas of our business to drive growth and market adoption.

In addition, a strong balance sheet puts us in a better position with respect to potential acquisitions and licensing agreement. We continue to be pleased with our financial and operating performance. We’re making progress to advance in many areas of our business and now having improved financial foundation from which to build on the momentum we have achieved. We are confident that 2014 will be another exciting year of growth for iCAD.

With that financial overview, let me now turn the call back to Ken. Ken?

Ken Ferry - Chief Executive Officer

Thanks Kevin. As our financial performance illustrate, 2014 is off to a good start. We have multiple initiatives underway to capitalize on the momentum in the Therapy business and to leverage instrumental business from a customer base in Cancer Detection, that number is nearly 4000 systems and growing. So, let me start with a discussion of our Therapy products. Our Therapy business continues to gain momentum, driven largely by the growing demand for the use of the Axxent Electronic Brachytherapy System for the treatment of non-melanoma skin cancer. We’re very pleased to report that this year’s first quarter, skin system placements grew 50% over last year’s first quarter.

And we recently announced that more than 4000 non-melanoma skin cancer patients have been successfully treated using the Xoft System. As a recap, the Xoft System offers a painless non-surgical option for the treatment of non-melanoma skin cancers. Typically, at least this is treated for 45 minutes twice per week for four weeks with excellent clinical and cosmetic outcomes. The current standard of care by comparison is most surgery which were clinically effective and often be associated with scarring particularly on cosmetically sensitive areas such as the nose, ears, and face. As I just mentioned, thousands of patients have benefited from this non-surgical option.

In addition, we continue to be encouraged by the growing body of clinical data supporting the use of the Xoft System as an option to treat non-melanoma skin cancer. Significant clinical data has been presented at recent prestigious medical conferences highlighting the demonstrated success of eBx. At the American Academy of Dermatology Annual Meeting in March, Dr. Ajay Bhatnagar presented clinical outcomes data on 187 patients and 275 non-melanoma skin cancer lesions treated with the Xoft System showing zero recurrences with excellent cosmetic outcomes up to three years post-treatment. Also, at the American Society of Brachytherapy Annual Meeting in May, Dr. Stephen Doggett presented the results of his study on 364 patients with 561 lesions treated with the Xoft system. Patients were treated with 8 fractions of eBx with excellent clinical and cosmetic outcomes with up to 19 months post-treatment follow up.

Of the more than 3 million cases non-melanoma skin cancer that are treated in the U.S. per year, we estimate the addressable market for the Xoft System to be approximately 1 million cases. This continues to represent a very large market opportunity for the use of Xoft system, as we continue to invest in targeted initiatives that will increase awareness and drive clinical adoption. Studies such as these just reference providing important clinical evidence to drive adoption among other physicians and are necessary to support a favorable and more widespread reimbursement. For skin cancer treatment, there were currently 19 stage with positive Medicare payment policies. We have an active strategy underway to expand the reimbursement coverage to the 31 states would have either a silent or negative policy.

Strong support of clinical data such as these studies, are a key to expanding coverage nationally. We recently had strong presence at the American Academy of Dermatology’s Annual Meeting, highlighted by the presentation of Dr. Bhatnagar’s data. We came away from the meeting highly encouraged about the growing interest in the Xoft System for the treatment of non-melanoma skin cancer. We also validated a need to continue to expand our efforts with regard to physician awareness and education. So, to this end, we will continue to invest and expanding our sales and marketing efforts which really could have variety of activities to reach and influence our target audience of dermatologists and radiation oncologists. An example being our physician seminars led by radiation oncologists in collaboration with dermatologist that educate other physicians on how to corporate Xoft into their practices. We will continue to expand these programs regionally as reimbursement grows. We also continue to participate in important medical meetings to bring together relevant specialists. For example, our team was at the Mohs College Annual Meeting that was held in Phoenix last week.

So, in summary, we expect the combination of more positive clinical data along with an enhanced awareness and education at the physician specialty level will accelerate market adoption for the Xoft System for the treatment of non-melanoma skin cancer. Shifting topics to the Xoft System for the treatment of early stage breast cancer, we saw continued growth in procedure volume, but the first quarter balloon applicator unit growth of 17% compared with last year’s first quarter. We’re pleased with this continued growing procedure volumes demonstrate the success the sites are having once the programs are up and running and treating patients. That said, we are continuing the investments in targeted programs, increase awareness and educated physicians on the benefit of offering IORT to their patients that fit the clinical criteria.

As with the treatment of skin cancer, we continue to invest in awareness and educational programs in breast IORT. We recently hosted an educational symposium at the Miami Breast Cancer Conference which is one that premium medical meetings for breast cancer surgeons and our symposium resulted in consumer interest and growing sales activity. Last week, we exhibited the American Society of Breast Surgeons in Las Vegas and follow the event by participating at the American College of Radiology’s National Conference on breast cancer in Phoenix. As you can see, we are reaching all specialists who diagnose and treat breast cancer patients. Importantly, our participation in these meetings allows us to interface directly with physicians to communicate the benefits of offering breast IORT to their patients.

In addition, we will continue to promote best practice sharing from a number of IORT sites that have establish successful in growing programs in their area. Patient enrollment in our multi-center clinical trial evaluating the safety, efficacy and cosmetic outcomes using these options and to treat early stage breast cancer continues to go well. We remain on tract to have approximately 500 patients enrolled by the end of this quarter and expect to report the interim data from this perspective study some time at 2015. Again, post-marketing studies such as this enhance awareness of breast IORT and support increasing adoption. As I mentioned, we are early on in the adoption curve for the Therapy business. With significant opportunities ahead in both non-melanoma skin cancer and early stage breast cancer, we expect to see continued strong growth in this business throughout the balance of 2014.

Turning now to our Cancer Detection business, we continue to make solid progress on our plan to leverage the considerable market opportunity inherent in our install base which is considerable to product upgrades and service contracts while preparing for the longer term growth from the industry shift to tomosynthesis or 3D mammography from the current 2D digital mammography technology. Recurring revenue in our Detection business continue to show solid gains in Q1 as we increased sales of upgrades and new agreements to our substantial install base. This category should continue to generate increasing revenue as our next generation mammo product PowerLook is gaining traction as a replacement for the prior generation product or in conjunction with adding breast density capability.

MRI sales through our partnership with Invivo were the strongest to-date relieved by growing progress in use of MRI and prostate cancer detection. There is significant market opportunity for extended use of these technologies as there superior diagnostic capabilities become more widely accepted for prostate cancer diagnosis and treatment planning. The progress in MRI was offset by weaker international revenue and declining analog sales. We do expect digital mammo CAD revenues to be relatively flat in 2014 and to pick up an early to mid 2015 as we launch our first mammo workflow tools for the interpretation of tomo or 3D mammo images.

So, we remain very excited about the future with the markets expected conversion from 2D digital to 3D digital mammography. And look forward to offering a sweet of workflow tools for the interpretation of 3D images. This opportunity should be considerable as we like in to the analog to first generation digital market conversion which afforded us considerable growth over number of years as our CAD tools were sold nearly one to one basis with the new 2D machines. So, in closing, our strategy remains steadfast, continue to focus on market adoption that will drive strong growth in the Therapy business to a range of targeted initiatives while getting the Cancer Detection business back to a higher growth mode to the introduction of 3D mammo interpretation tools.

So, with that, operator we like to open up the lines for calls.

Question-and-Answer Session

Operator

Alright. (Operator Instructions) And Ken or Kevin maybe you would like to make a comment or two kind of while we wait for some questions to formulate. And I actually stand correctly, it does look we are – it does look like we have question coming in from the line of Brian Marckx with Zacks Investment Research. Please proceed.

Brian Marckx - Zacks Investment Research

Hi, guys. Congratulations on the quarter. Ken, did I hear you right about the tomo product that you expect that to launch now in 2015?

Ken Ferry

I think, Brian the way we’re looking at it is probably international release. It could be as soon as late in Q4 of this year. I think, as we look at a range for the United States, it’s probably somewhere in that Q1 to Q2 range next year, it is going to largely be driven by the FDA clearance process. So, our timeframe really hasn’t changed. What has probably occurred is that we’ve been able to make the progress we need on the international front and understand the implications from a regulatory standpoint to be confident with a late 2014 early 2015 launch. I think in the United States, it’s still a bit early relative to the clearest definition of the regulatory path. And so, we’re probably a little bit more cautious, but I would say in our next quarter’s call, I should have a better handle in more clarity on where we see the U.S. timing.

Brian Marckx - Zacks Investment Research

Okay, great. Relative to the Therapy business, the product Xoft instrument sales was I guess relatively soft in Q1 but the services and supplies was extremely strong. Can you talk about what you’re seeing as far as demand goes and what does those numbers reflect in terms of demand? I know some of this can be kind of lumpy, particular in the services and supplies. How much is that sort of lumpiness and how much of that is kind of the more fundamental demand I guess?

Ken Ferry

Right. Yes, I guess I would start Brian by making a few comments on system placements. We sold one more system in the first quarter than we did in the first quarter of last year. So, we did have modest increase in system sales. We also did have an increase of 50% in skin sales. So, obviously the drop-off slightly was in breast IORT sales. But, that was also after we sold 14 systems in the fourth quarter of last year. So, when you look at that combination of the fourth quarter and the first quarter, you could easily see a two quarter run rate around 50 systems having sold 44 last year. So, we certainly anticipate strong new system sales over last year. With that said what you are seeing is a significant increase in procedure volumes related to the skin market. And, when you do that, the amount of source usage x-ray source usage is pretty considerable. And those customers are typically as they’re rapidly buying these very large source agreements, some up in the range of around to 100K. So, I think what you’re seeing is this growing number of sites and you’re also seeing growing number of procedures on those sites simultaneously which is really driven considerable amount of increase again in source revenue.

Secondarily to that, you’re seeing an increase in service contract revenue because a lot of these systems that we sold over the last couple of years now, moved from warranty to service. So, we’re starting to see some very, very strong growth in service contract revenue. And then, obviously, on the balloon applicator side, we had a strong increase, we actually had 21% more applicators sold in the first quarter versus the first quarter of last year. And, our average selling price continues to be favorable for those. So, a lot of factors have gone into the recurring revenue growth and therapy. It all stems from two fundamental things, one is increasing the number of systems install and increasing the volume of patients that are being treated on those systems which to us is very encouraging and indicating successful programs that are underway and continuing to build even additional momentum because so many of these systems have plenty of capacity left in that. So, we felt very good about the quarter. New placements were good. Recurring revenue was substantially better. And we feel well positioned to have a strong in both in terms of new system sales as well as recurring revenue type areas that I just mentioned.

Brian Marckx - Zacks Investment Research

Is it conceivable that you can do kind of $2 million per quarter run rate through the remainder of 2014 on the service system and supplies Therapy business?

Kevin Burns

Hi, Brian, it’s Kevin. So, we ended the quarter with 2.2 and the way we think about that number is, it’s going to be additive, right. So, we do believe I mean it’s going to be growing from there. That is revenue from our existing customer base. There is about 10 to 12 customers who are – that we sold systems to who are not yet active and clinically treating. That will add to our $2.2 million run rate. In addition, we’re going to be adding new customers throughout the course of the year. So, this 2.2 is really a base and again we’ll add existing customers as they come onboard from a source revenue standpoint, and as we sell new systems, it’s going to continue to grow. So, we expect this to grow very nicely sequentially going forward.

Brian Marckx - Zacks Investment Research

So 2.2 should be kind of a low end number, okay. That’s a really, really good number. Okay. Good.

Kevin Burns

One other comment on that – one other comment on that Brian, is as we move forward, the way you want to think about a system placement of the recurring revenue, addition is every system typically generate about $100, 000 of recurring revenue. And the mix is slightly difference between skin and the breast market. On an average, each new system placement, that is we like to additional recurring revenue, that’s going to be added to our run rate.

Brian Marckx - Zacks Investment Research

Okay, that’s really good news. You alluded to – on the cash balance, you have a pretty sizeable cash balance at this point and you alluded to in your prepared comments that you maybe looking at acquisitions or kind of other opportunities. Is there more that you can talk about that maybe you have – that you are already looking at or that you are considering at this point?

Ken Ferry

I guess, the way I would answer, Brian, is it, let’s say, when you are in a large market, obviously in the early stage , you’re trying to see the market and you’re also trying to anticipate growth opportunities that are very ancillary, very complimentary, very synergistic to that core market. So I just say philosophically, the way we look at the business is we want to provide a lot more than just a box that delivers therapy. So, that could be a range of software capabilities and services that are beyond the services that we offer today to our sites that all have these varying degrees of needs. So, I think we’re looking I guess a open-minded passion that how over time we can increase our solution offering if you will to the skin market in particular and try to get a overall growth from other areas that are very natural relative to the workflow as well as the services that need to be provided. So, we’re taking a look at the category, I wouldn’t say we have completed the evaluation we are in a kind of real-time assessment mode. But, clearly we’re committed to the market. We want to have more to offer in that market. So, things like software and services, they’re probably high in our list from an investigation standpoint.

Brian Marckx - Zacks Investment Research

Okay. Okay. That’s all I have. Thank you very much.

Kevin Burns

Thanks Brian.

Operator

Alright. So, it looks like we have another question coming in from the line of Bill Bonello with Craig-Hallum. Please proceed.

Bill Bonello - Craig-Hallum

Thanks, guys. Got a little trouble with the buzzing in with the mics. So, just a question on the utilization, just a follow-up, what you were just talking about? You mentioned that maybe there’s 10 to 12 units out there that aren’t really being used. Beyond that, what kind of ramp in utilization are you seeing over time at existing customers? In other words, are you seeing that once they get going or they getting going at sort of a full production or do they tend to use it with more patients as time goes by?

Kevin Burns

Hi, Bill. It’s Kevin. Just to be clear on the 10 to 12 that are out, not being utilized. Note that there’s systems that are in the normal course of getting onboard and customers are getting enough speed. They’re putting their customers or patients in a cue to be treated and they’re getting it done with the new state regulation. So, nothing, nothing noteworthy there. I just want to make sure you understood that. And then second is, we’re seeing a whole range of uptake. We are seeing a majority of our customers are 75 if not, greater percent growing their patient volume month on month.

Typically, what we’re seeing them start out with it between 46 patients per month that sort of their, what we considered onboarding rate to get comfortable with the system and the patient treatment. And then there going to on a month to month basis after that and a lot just depends on each site. Our highest utilization sites are treating upwards of 25 customers per month, 25 patients per month excuse me. So, they’re growing from 4 to 6 patients per month upwards that 25, 30 patients per month and that’s on the higher end.

Bill Bonello - Craig-Hallum

Okay. And do you think I mean, is that the kind of target you think a lot of the practices could get at or is that just because those happen to be a very large practices and don’t think of that as sort of a target utilization?

Kevin Burns

No, I think each practices you make and it depends on the size of the practice locations and they may have a lot of surgeons there as well. So, I think every situation at this point is unique. And again, we’re still in the early stages as you know, right. We only have about 60 systems out there treating at this point in the skin market. So, our data and our uptake numbers are – we are still learning about the market as we go.

Bill Bonello - Craig-Hallum

Sure. Absolutely. And then, just Ken touched briefly on kind of the placements and maybe looking out forward. I know you were at a number of -- and you mentioned it -- to a number of different trade shows in the first quarter, a couple on the breast side and a big one on the dermatology side, but those tend to be catalyst or replacements and could we actually see sort of an uptick in controller placements as we look at the second quarter or are there down the year?

Ken Ferry

I think it’s a mix Bill. I think you’ve got situations where some of the customers there are well down the path of making a decision and they come into either validate or ask additional questions as part of their final process. One of those that are coming in, aware of the technology would like to adopted in their practice and are in the process of making a decision in that regard over some period of time neither individually or with their partners. And then you’re introducing it to a lot of people that really don’t have a lot of knowledge. These early stages clearly and skin as an example, led the Academy of Dermatology Meeting. This was brand new information to a lot of dermatologist. And to some, it was, faintly aware and I’ve know radiation has been used many, many years using different technology platforms and so forth to treat patients. So, you get a really wide range.

So, I think there is some short-term benefit, but the benefit to be truthful as more medium and long-term at these meetings. And, I look at them as probably making more of a contribution to awareness and education right. But then, certainly our deals that will happen as a result, and it will happen this year. So, we will see some incremental business as a result of our presence but I would say given some of the sales cycles for capital can be longer. A lot of the business also is some that will take time to develop. So, it’s well worth our efforts to be there because we’re accomplishing a lot. In a mature business, that’s in a standard of care environment, all you’re looking at is how many leads did you get out of your trade show exhibit and how is that compared to last year, right. In our case, we’re trying to educate, create awareness, create visibility. So, but at some point in the next let’s say 6 to 12 months, there’s this big snowball effect. And so, it’s a much broader goal, lot more to do given the level of adoption we’re at today.

Bill Bonello - Craig-Hallum

Okay. And then just a follow-up on that, thinking of your efforts to penetrate in the other geographic markets in the last quarter, having mentioned the majority of cases coming from a handful of states, are you -- are you present in the other states where there is positive reimbursement decisions? Are you actively out making sales efforts or are your partners actively out doing that or is that – is that essentially territory that has yet to be touched by you?

Ken Ferry

It’s probably a mixture, obviously of 19 states positive policy and probably three or four states generating the majority of your actual business today. So, given the size of our company to be feet on the ground in 15 states knocking on doors is probably not realistic at the moment. But, we’ve done a lot electronically, a lot in these larger medical conferences to reach people that are in those states. And we are trying to call directly on some of the large practices and we know that would be great candidates. So, we’re in all of those states in some fashion, now some with feet on the ground and electronic communication and follow-up from the medical meetings and some combination or lack thereof of those initiatives. So, we’re definitely there. It just takes time, we’re also realistic about – it’s taken us roughly couple of years to develop the western coast market.

But, I think the other states while you may not see, let’s say, in some of the Midwest states the levels of skin cancer you might see in the West Coast and California is an example. They’re great markets to participate in. So, we expect to start seeing sales from a number of states, just probably as soon as this quarter indicating new opportunity in these other states that where we have a more recently received the positive news on reimbursement. But, we’re – we touched them all, we’re going after all the large practices, our partners are very present in those states as well as our direct sales people. But, we’re just beginning the sales process for a lot of the customers outside let’s say the western region. So, it will take some time, but we definitely are very active in all states and have a positive payment policy.

Bill Bonello - Craig-Hallum

Okay. It’s very helpful. And then just a last question, I know there’s been some discussion of the use of IORT, on the breast cancer side as a bump prior to some additional external beam treatment. I’m just curious if you can comment on that at all if that’s something you’re seeing any traction with yet and whether you think that might be something that would help boost the adoption of sales on the breast side?

Ken Ferry

Yes, I mean I think if you look historically, a boost prior to giving a full regimen of whole-breast radiation has been very common for many years, the main point being well that probably not using electronic brachytherapy, right, but using radio invasive therapies. So, it’s been fairly common and there is a number of studies had been published showing the benefits of boosting the patient at the time, if you will, the lumpectomy and then having follow-up or doing it superficially post-lumpectomy. Where we look at it as an opportunity is there’s about a 100, 10 1000 of a 40% of the newly diagnosed patients that’s fit the clinical criteria for monotherapy which is just IORT. You can add 80 or 90,000 patients to that population if you use that as a boost and then use it in conjunction the whole-breast radiation.

So, you might actually get being able to treat close to let’s say 200,000 patients as oppose to say 100,000 or 110,000. You have to establish the proper clinical criteria, obviously having some sort of study data which would help to titrate the dosing relative to how much you’d given a boost versus how much the follow-on whole-breast therapy would be, would it be the full five or six weeks, will it be shorter regimen, depending on what you’re trying to accomplish. And so, they really are not studied yet using electronic brachytherapy as a boost but there are other similar technologies which we can drive from as well as expert panels that have the experience in that area. So, we’re very much investigating how we could establish a clinical protocol where our technology could be used as a boost in conjunction with whole-breast.

If we’re able to get that done successfully in the next, let’s say in the next year or so, it could expand our addressable market by a significant number where instead of roughly a 100,000 patients, we maybe closer to 200,000 patients per year in the domestic market, that could be candidates. But, we need to work through their proper establishment of protocol with the treatment combined if you will between IORT and whole-breast, outpatient would be. And then, we need to be able to follow those patients in some sort of a study, so that over time, we cold make a concrete recommendations based on outcomes and recurrence rates. So, it’s a longer term opportunity but one that we’re very interested in.

Bill Bonello - Craig-Hallum

Okay. Great. Thank you very much.

Kevin Burns

Okay.

Operator

Alright. So, it looks like we have another question coming from the line of Jeb Terry with Aberdeen Investment Management. Please proceed.

Jeb Terry - Aberdeen Investment Management

Yes. Good afternoon, Ken, Kevin.

Kevin Burns

Hi, Jeb.

Jeb Terry - Aberdeen Investment Management

Kevin, I think you mentioned something -- apologize, I had some distraction, I was late on the call. But, did you say something about a plan to charge on a per procedure basis?

Kevin Burns

So, one of the things that we’re exploring and we had a few proposals last year, some larger academic institutions is actually in order to help them bring onboard in IORT system. We’re looking at different pricing models and one of those is that per procedure or a subscription type model. So, we believe by offering some of these in selected situations, it will increase adoption and utilization in the breast market.

Jeb Terry - Aberdeen Investment Management

In the breast market. Okay.

Kevin Burns

Right.

Jeb Terry - Aberdeen Investment Management

And a question on the – in the skin business, I know, in the past, there were some interest on multisite dermatology practices possibly radiation oncology practices. Is that still the case that you’re seeing some traction and in sales in multisite customers and are there multisite customers that are coming back and kind of building out their footprint, if you will? And if so, might there be some visibility into future controller placements with existing multisite players?

Kevin Burns

We, again, we have quite a few large dermatology group, so at 5, 10, even a 15 facilities. Some of them have expected interest in expanding systems to all of their facilities, right. And right now they may have more than two or three systems, they maybe sharing them across in centers. So, we definitely believe that there is significant opportunity just in our existing customer base alone. And, I think we probably have four, five large groups that I’d say are in a process of – proving the technology and then rolling, they have a plan to roll it out over the next 6 to 12 months. But, I don’t think we’re going to be sharing any additional detail in terms of system placements, we’re not but it’s a great opportunity for us getting in to these larger derm groups where they’ve proven in one center and then everybody else wants to bring it onboard in the other facilities.

Jeb Terry - Aberdeen Investment Management

Right. Okay.

Ken Ferry

Jeb, I would also add that we are still seeing demand from the radiation oncology groups. And, often it’s a combination of their marketing these services to the dermatologist. And they’re also in some cases, marketing the service directly to the patients and their region. So, I definitely see two call points from a sales standpoint, one is Kevin mentioned dermatology practices in expanding. We have a number of examples where they were sharing a machine between sites and now they decided to buy incremental machines because they’d reached sufficient volume that they don’t want to move them around.

And at the same time, we’re seeing strong interest still from radiation oncology wanting to put a system off and in their own facility where they treat a wide range of radiation cases and have a relationship either directly with the patient or with dermatologist. They refer patients to them. So, we’re really seeing both models. I would say the system going in to the dermatology office, those are probably more common than in the radiation practice. Although, I think again we’re trying to really take advantage of both call points because you need both physicians involved to have a successful treatment strategy.

Jeb Terry - Aberdeen Investment Management

Right. So if a dermatologist comes in and says I’d like one and he’s going to have to bring in -- he’s got to have a radiation oncology partner, right, is that still the case?

Ken Ferry

Yes. And so that’s where lot of our service providers come from. So, when you hear the names, DermEbx and ARS and Vantage and so forth, what you’re realizing is that when the derm is really interested in kind of shows a direct interest, we have service providers that can bring that whole clinical paradigm together.

Jeb Terry - Aberdeen Investment Management

And just curious, what’s the headcount now for Xoft itself and could you give us a sense for kind of how the – if your headcount is building – going after those multiple states and then following up with these multisite actors, I guess there is a service element associated with it as the more it comes off and of course you got to have, some individuals dedicated to serving each of these sites to incur – to encourage increased utilization and then just provide ongoing great services and that type of thing.

Kevin Burns

We don’t break it out by business area, however Jeb, it’s growing the business by about 10 people over the last four months or so and all of that growth has been in the Xoft business.

Jeb Terry - Aberdeen Investment Management

Okay.

Ken Ferry

Mostly health and service.

Kevin Burns

Right.

Jeb Terry - Aberdeen Investment Management

Okay. And in terms of reimbursement outlook, if I understand that these situation, is it proper to view that is that meaning that IORT reimbursement would be additive to the more conventional reimbursement that a radiation oncology gets with whole breast radiation therapy (indiscernible) is fade off. Is that the point of the addressable market increase?

Ken Ferry

Well, I think what we’re seeing is it’s really driven by clinical criteria sites of tumor whether is an invasive cancer versus not and so forth just as we have a good criteria for monotherapy but I guess what I would envision it happening, hence that radiation oncologist would get paid as they do today, delivering the IORT boost in the operating room. And then they would also collect obviously their fees for the number of fractions delivered on outpatient basis. So, you could say that, yes they would in some get more reimbursement, our hospitals get more reimbursement depending on what side you’re looking at professional versus technical fees. So, that’s certainly is in there which I think would alleviate one of the hurdles which is where radiation oncology looks at it all and nothing, I do monotherapy or with IORT or I do whole breast.

And, clearly for the number of fractions treated in whole breast, they get paid a lot more money. So, I think that provided we can prove this clinical paradigm is going to be very powerful and effective. You probably then remove one of the financial barriers to adoption which has been the receptiveness of radiation oncologist to make the effort to get off to the OR and scrub in coordinated fashion and deliver therapy and get paid around $500 for their effort versus the several thousand dollars they get for delivering a multi-fraction therapy in their centers.

Jeb Terry - Aberdeen Investment Management

That was a great development. Very good. Well, congratulations on the 95% increase in therapy service and supply and apparently, yes, you got a runway for that to continue with the 10 to 12 sites that’s getting up and the organic growth in the existing sites, that sounds terrific. Thanks a lot, guys. Congratulations.

Kevin Burns

Thanks, Jeb.

Ken Ferry

Thanks, Jeb.

Operator

Alright. So, it looks like we have no further questions at this time. So, I’ll go ahead and turn it back over to Ken Ferry, for closing statements.

Ken Ferry - Chief Executive Officer

Thank you, operator. Well, we’re very pleased with our overall progress, particular, as it relates to the Therapy business and the treatment of non-melanoma skin cancer. We really had a number of quarters in a row of growing a new system placements, significant increase in procedure volumes, and recurring revenue. We’re also seeing nice progress on recurring revenue in our Cancer Detection business. And we’re working feverishly to have workflow tools available for the 3D or tomosynthesis mammography market as it develops further over the next years. So, I think our overall progress is strong, we’ve shown some very good success against our strategy, our growth has been solid, and we think we’re at the early stage of adoption in number of these markets. So, we should be able to sustain this growth rate over a longer period of time and ultimately deliver more shareholder value. So, I’d like to thank everybody for your continued interest in iCAD and participating in today’s call. And we look forward to updating you again at the end of our second quarter on our Q2 results call. So, good day, everyone.

Operator

Alright. Ladies and gentlemen that does conclude today’s conference. Thank you all for your participation. You may now disconnect. Everyone, have a great day.

Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.

THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

If you have any additional questions about our online transcripts, please contact us at: transcripts@seekingalpha.com. Thank you!

Source: iCAD's (ICAD) CEO Ken Ferry on Q1 2014 Results - Earnings Call Transcript
This Transcript
All Transcripts